All In Biotech

Investigational drug · Phase 2

Linrodostat

Also called: BMS-986205

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

24

Any phase or sponsor naming "Linrodostat"

First trial start

2018

May 30, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Linrodostat", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Cancer

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Linrodostat" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 36 on PubMed

Also in development for Advanced Cancer

  • ObrixtamigBI 764532Phase 36 trials

    Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology

  • EzabenlimabBI 754091Phase 32 trials

    Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors

  • ALK201Phase 22 trials

    Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors

  • CVM-1118TRX-818Phase 22 trials

    TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors

  • KB707Phase 22 trials

    Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV

  • LY188011Phase 22 trials

    Eli Lilly · Neoplasms, Child, Adolescent

  • Seqker Biosciences, Inc. · Solid Tumors, Advanced Cancer, Recurrent Cancer

  • TST001Phase 22 trials

    Transcenta Therapeutics (Hangzhou) Co., Ltd. · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.